In comes, DeepSeek, a Chinese AI startup that has shown it is possible to develop AI models without spending much. It ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

MeiraGTx Holdings plc has recently released its 10-K report, offering insight into the company's financial condition and ...

BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...

Hologen has committed up to $430m in funding to support the development and commercialisation of AAV-GAD, MeiraGTx’s ...

MeiraGTx (Nasdaq: MGTX) has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the ...

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.

Reports FY24 revenue $33.279M vs $14.017M last year. “MeiraGTx (MGTX) demonstrated excellent execution in 2024, marked by significant ...